|| List of recent Acetate-related patents
| Composition and method for treating dry eye syndrome|
The present invention provides for compositions, medicaments, and methods for treating or alleviating the symptoms of dry eye syndrome or chronic dry eye. More specifically, the present embodiments provide for medicaments consisting of tocopherol or tocotrienol eyedrops.
| Stain removing solution|
A solution having improved stain removing properties on hard surfaces, carpets and fabrics, that is easier to handle (stored or transported at lower temperatures and less corrosive) and that is environmentally friendly. The stain removing solution includes the following components: a surfactant selected from the group consisting of alcohol ethoxylates, alkyl sulfates, alkyl ether sulfates, alpha olefin sulfonates, alkyl phosphates, alkyl amidopropyl betaines, alkyl betaines, amphoacetates, amphoproprionates, amphosulfonates, amine oxides, alkanolamides, sulfosuccinates, and sultaines, a hydrotrope, and a solvent.
| Bulletproof fabric and method for producing the same|
Disclosed are a bulletproof fabric and a method for producing the same that exhibit improved anti-traumaproperty and minimize deterioration in bulletproofness even after use under harsh conditions for a long period of time. The bulletproof fabric includes a fabric comprising at least one high-strength fiber selected from the group consisting of a high molecular weight polyethylene fiber, an aramid fiber, and a polybenzoxazole fiber, and a water repellent layer disposed on the high-strength fiber, wherein the water repellent layer is formed by treating the fabric with a water-repellent agent comprising fluorocarbon and a hardness-enhancing resin, and the hardness-enhancing resin is a polyvinyl acetate resin, a polyester resin, a polyacrylate resin, a melamine resin, or a mixture of two or more thereof..
| Biocatalytic process for preparing eslicarbazepine and analogs thereof|
The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.. .
| Polydiorganosiloxane-encapsulated active ingredient, method for the preparation thereof, and chewing gum comprising same|
Delayed release in chewing gum of an active ingredient, such as a sweetener or a food acid, is provided by encapsulating solid particles of the active ingredient in a polydiorganosiloxane. The resulting polydiorganosiloxane-encapsulated active ingredient includes a continuous phase with the polydiorganosiloxane and a disperse phase with the solid particles of the active ingredient.
| Mold and mildew stain removing solution|
A solution having improved mold and mildew stain removing properties on hard surfaces, that is easier to handle (less corrosive and less malodorous) and that is environmentally friendly. The mold and mildew stain removing solution includes the following components: a surfactant selected from the group consisting of alcohol ethoxylates, alkyl sulfates, alkyl ether sulfates, alpha olefin sulfonates, alkyl phosphates, alkyl amidopropyl betaines, alkyl betaines, amphoacetates, amphoproprionates, amphosulfonates, amine oxides, alkanolamides, sulfosuccinates, and sultaines, a solvent, and at least one chelating agent.
| Dialysis preparation|
The present invention provides a pharmaceutical composition for dialysis wherein the decline of ionized calcium concentration in an acetate-free bicarbonate dialysate comprising no acetic acid and/or sodium acetate is controlled. The present invention further provides a dialysis agent a that comprises electrolytes, citric acid and/or citrate as ph adjuster, and/or glucose, for preparation of bicarbonate dialysate; the agent a characterized by being adjusted by citric acid and/or citrate so as to keep the electrolyte ionized calcium concentration not less than 1 mmol/l in a prepared bicarbonate dialysate.
|Process for preparing di-substituted succinates|
The invention relates to a process for preparing (2,3) disubstituted succinates that allows (2,3) disubstituted succinates to be obtained in good purity and with acceptable reaction yields. The (2) and (3) substitutions may be the same or different.
|Flame retardant cellulose acetate|
Flame retardant cellulose acetate is prepared comprising cellulose acetate flakes and an organophosphate compound bonded to the cellulose acetate flakes. Accordingly, the bonded phosphate-functional group provides the cellulose acetate flakes with pendant phosphate ester functionality.
|Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use|
The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight.
|Polymer product and the use of the same as dispersing agent|
The invention relates to a polymer product obtained by polymerization of i) at least one monomer selected from n-vinylformamide and vinyl acetate, and ii) maleic anhydride to give a copolymer comprising n-vinylformamide and/or vinyl acetate and maleic anhydride followed by hydrolyzing formamide groups originating from n-vinylformamide to amino groups and/or acetate groups originating from vinyl acetate to hydroxyl groups and acid anhydride to dicarboxylic acid groups to give a water-soluble copolymer comprising amine and/or hydroxyl and carboxyl groups, wherein the molar ratio of the n-vinylformamide and/or vinyl acetate monomer to the maleic anhydride monomer is from 70:30 to 30:70. The polymer product can be used as a dispersing agent or as a scale inhibiting agent..
|Characterizing a glatiramer acetate related drug product|
Thereby characterizing the glatiramer acetate related drug substance or drug product of step a).. .
|Pet-c based security laminates and documents|
A security laminate (1) including in order a transparent oriented polyester support (2), a subbing layer (3) and an adhesive layer (4) which is coated on top of the subbing layer, wherein the binder of the adhesive layer is based on a mixture of a first and a second polymer in a weight ratio from 50/50 to 90/10, wherein the first polymer is a copolymer comprising vinyl acetate and at least 85 wt % of vinyl chloride based on the total weight of the first polymer; wherein the second polymer is a copolymer of styrene, butadiene and methylmethacrylate or a copolymer of vinyl butyral, vinyl acetate and vinyl alcohol; and wherein the binder of the subbing layer is based on a polyester-urethane copolymer.. .
|Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities|
The present invention provides for microbial compositions and methods for reducing the concentration of short-chain fatty acids in the gut as a way to reduce energy uptake and manage obesity. More specifically, the invention provides for decreasing short-chain fatty acids available for absorption in the human gut, such as acetate, using one or more of: a probiotic including a homo-acetogenic, acetate oxidizing bacterium that converts acetate to h2; a probiotic including an acetoclastic methanogen; a microbial electrolysis cell comprising a homo-acetogenic bacterium and/or an acetoclastic methanogen; a prebiotic that enhances the growth or function of acetate-scavenging microbiota; or a highly selective antibiotic that targets h2-oxidizing methanogens..
|High performance hotmelt window sealant|
A hot applied, non-crosslinking, non-butyl, sealant. These sealants are composed of olefin polymers, styrenic block copolymers, an ethylene vinyl acetate copolymer, tackifying resins, plasticizers, and preferably inorganic fillers, and organosilane adhesion promoters.
|Solid dispersions of amorphous paroxetine mesylate|
The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10.
|Composite article and method for making same|
A composite article includes a ceramic part, a plastic part, and an adhesive layer connecting the ceramic part to the plastic part. The adhesive layer includes polyvinyl acetate, polyvinyl alcohol, dibutyl phthalate, and sec-butyl acetate..
|Method and composition for road construction and surfacing|
Methods and compositions for improving the strength and longevity of secondary roadways through environmentally sound practices are disclosed herein. A composition for road sealing includes acrylic and vinyl acetate powdered polymer mixed with native soil..
|Cellulose acetate compositions|
The present invention relates to compositions comprising a blend of cellulose acetate 5 and a water soluble polymer. In some embodiments, the composition is water dispersive and/or biodegradable.
|Biphenyl acetate, preparation and uses thereof|
A biphenyl acetate composition, which is a biphenyl acetic ammonia butantriol salt. The composition is prepared by reacting biphenyl acetic acid and ammonia butantriol in organic solvent, and a ratio of biphenyl acetic acid and ammonia butantriol is 1:1.
|Method for preparation of iloperidone and crystallization method thereof|
A method for preparation of iloperidone is provided which comprises reacting 6-fluoro-3-(4-piperidinyl)-1,2-benzoisoxazole hydrochloride with 1-[4-(3-chloropropoxyl)-3-methoxyphenyl]ethyl ketone in an inorganic alkaline aqueous solution. A crystallization method of iloperidone is also provided which comprises adding seed crystal to the iloperidone solution in ethyl acetate, and then iloperidone crystal is obtained with high purity by controlling the temperature and the stirring speed..
|Polymer and method for using the same|
The invention relates to a polymer derived from: reaction of glycidyl (meth)acrylate, allyl glycidyl ether or [(vinyloxy)methyl]oxirane with ammonia or primary amine to obtain a mixture of monomer compounds; reaction of the mixture of monomer compounds with at least one of acrylic acid, vinyl alcohol, vinyl acetate, acrylamide, methylacrylic acid, and methylacrylamide to obtain an intermediate polymer; and reaction of the intermediate polymer with a dithiocarbamic acid salt. Methods for using the polymer are also described herein..
|N1,n4-bis(buta-1,3-dienyl)butane-1,4-diamine pharmaceutical compositions and methods thereof|
N1,n4-bis(buta-1,3-dienyl)butane-1,4-diamine dihydrochloride (also referred to as mdl 72,527 and n,n′-di-2,3-butadienyl-1,4-butanediamine dihydrochloride), or salts or solvates thereof, its use as an antioxidant, its use in preventing and/or treating prostate cancer in male humans, and its use in reducing the concentration of reactive oxygen species in human prostate gland tissue or any other body tissue, and methods of making the compound thereof are disclosed. Other disclosed methods include inhibiting acetyl polyamine oxidase in human prostate tissue or other human body tissue comprising administering a therapeutic amount of n,n′-bis(2,3-butadienyl)-1,4-butanediamine or a salt or solvate thereof to the human, and a method of determining oxidative stress in human prostate tissue or other human or animal body tissue comprising measuring a ratio of oxidized 2′,7′-dichlorodihydrofluorescein diacetate fluorescence:dna fluorescence and hydroethidine dye fluorescence ex vivo or in vivo..
|Pharmaceutical composition containing oleanolic acid acetate as an active ingredient for preventing or treating tlr- or il-6-mediated diseases|
The present invention relates to a pharmaceutical composition including oleanolic acid acetate or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating tlr- and il-6-mediated diseases, and a pharmaceutical composition including an adzuki bean extract containing the compound or the salt thereof, or a fraction thereof as an active ingredient for preventing or treating tlr- and il-6-mediated diseases. The adzuki bean extract or the compound of the present invention is derived from a natural resource that has been used as a natural medicine for a long time, and it is widely used for the development of prophylactic or therapeutic agents for tlr- and il-6-mediated diseases, for example, atopic dermatitis or arthritis..
|Sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof|
Disclosed is a sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof. The preparation contains ivabradine or pharmaceutically acceptable salts thereof and a sustained-release framework material, wherein the sustained-release framework material is selected from polyoxyethylene, or a mixture of polyoxyethylene and polyvinyl acetate or polyvinyl pyrrolidone..
|Multi-layered release formulation|
The present invention in general relates to a pharmaceutical dosage form comprising a multi-layered release formulation formed by co-extrusion. Said formulation in particular comprises a core layer comprising at least one polymer selected from polycaprolactone, ethylcellulose, or combinations thereof; and a coat layer comprising at least one (co)polymer selected from the list comprising: polyethylene oxide; polyethylene glycol; basic butylated methacrylate (co)polymer; a (co)polymer of polyvinylcaprolactam, peg and polyvinylacetate; or combinations thereof..
|Low formaldehyde vinyl ester/ethylene copolymer dispersions for use in adhesives|
Disclosed are low-formaldehyde aqueous dispersions of vinyl ester/ethylene, e.g., vinyl acetate/ethylene (vae), copolymers suitable for use in adhesives for applications such as tobacco or food products wherein only very low levels of formaldehyde are permitted. Such dispersions are prepared by emulsion copolymerization of a monomer mixture comprising a vinyl ester, ethylene, a stabilizing system comprising polyvinyl alcohol preferably having a degree of hydrolysis of at least 97 mole %, and a selected type of free radical redox polymerization initiator system.
|Peelable protective film and composition thereof|
A peelable protective film having perfect adhesion for providing temporary protection to objects is disclosed, which protective film having a peel strength ranging between 35 and 100 g/cm is capable of being easily peeled off from an adhered object and without leaving any residual adhesive; a composition containing a vinyl chloride-vinyl acetate copolymer, a high-molecular-weight emulsified, polymerized pvc powder, a low-molecular-weight emulsified, polymerized pvc powder, a trimellitate plasticizer, a diisobutyrate-based plasticizer, a phenol-free ca—zn stabilizer, fumed silica, aluminum hydroxide, barium sulfate and calcium carbonate is so suited for making the peelable protective film having a thixotropic index ranging between 2.00 and 2.20.. .
|Cellulose and cellulose ether solutions and use thereof|
Solutions of cellulose or cellulose ethers in solvent containing triethylheptylammonium chloride, triethyloctylammonium chloride, triethylhexylammonium acetate, triethylheptylammonium acetate, triethyloctylammonium acetate, triethylnonylammonium acetate and/or triethyldecylammonium acetate are provided. The solvent may further include up to 70 wt % of at least one organic solvent, with acetone being the preferred organic solvent.
|Titanium-containing ceramic paint and protective coating|
Disclosed is a titanium-containing ceramic paint, including 100 parts by weight of silica sol, 50 to 100 parts by weight of organic silane, 0.3 to 1 parts by weight of a catalyst, 5 to 20 parts by weight of titanium powder, and 1 to 5 parts by weight of a silicone oil. The organic silane can be methyltrimethoxy silane and/or methyltriethoxy silane.
|Heat-sealing cover film for packaging electronic components|
A cover film for heat-sealing to a carrier tape for carrying electronic components is described herein. The cover film comprises a polyester base layer, a first antistatic layer disposed on a first surface of the base layer, an intermediate bi-layer structure comprising a first intermediate layer and a second intermediate layer, the first intermediate layer disposed on a second surface of the base layer opposite the first antistatic layer, the second intermediate layer disposed on the first intermediate layer opposite the base layer, a second antistatic layer disposed on the second intermediate layer opposite the first intermediate layer, and a heat-sealing layer disposed on the second antistatic layer.
|Wetting enhancement coating on intermediate transfer member (itm) for aqueous inkjet intermediate transfer architecture|
Described herein is a method and apparatus for ink jet printing. The method includes providing a wetting enhancement coating on a transfer member.
|Methods and compositions for removing solids from hydrocarbon streams|
A demulsifying agent may be added to a hydrocarbon stream in an effective amount where the hydrocarbon stream includes a plurality of solids. The demulsifying agent may be added to the hydrocarbon stream at a location that is upstream from a desalter.
|Solar cell back-sheet and solar cell module|
Provided is a solar cell backsheet including a polymer base material, and a colored layer that is disposed directly on the polymer base material, and that contains a binder having an acid value of 2 mg koh/g to 10 mg koh/g and a pigment at a content of 2.5 g/m2 to 8.5 g/m2, and that has an adhesive force of 50 n/cm or more to an ethylene-vinyl acetate encapsulating material.. .
A sealant composition for insulation of devices that are sensitive to penetration of moisture from the external environment is described. The sealant composition has ethylene-octene copolymers, a maleic anhydride modified polyolefin, an ethylene-vinyl acetate copolymer, at least one inert filler, at least one moisture scavenger, and at least one stabilizing or antioxidant preserving agent..
|Group viii metal hydrogenolysis catalysts having low selectivity to ethers|
Group viii metal containing catalysts used in processes for producing ethanol from ethyl acetate by reacting the ethyl acetate with hydrogenation. The group viii metal containing catalyst has a selectivity to ether, especially diethyl ether, that is very low.
|Solid pharmaceutical compositions containing pregabalin|
A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration.
|Shear panel building material|
A shear panel building material that includes a first facing membrane, a core matrix disposed on a face of the first facing membrane, and a semi-rigid or rigid material attached to the core matrix. The core matrix can include microspheres having a size of about 200 microns to about 800 microns, sodium silicate, and ethylene vinyl acetate.
|Pharmaceutical compositions of dextran polymer derivatives|
Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative.
|Hydrophilic gum base|
A gum base comprising: a) a hydrophilic precursor component comprising hydrolysable units; and b) a copolymer of a hydrophilic monomer with a second monomer selected from vinyl acetate, isobutylene, isoprene, butyl rubber or styrene butadiene. This chewing gum base contributes to the ability of the chewing gum compositions and chewing gum products to degrade over time after chewing by imparting the chewing gum with increased hydrophilic properties..
The present invention provides a sterile solution comprising leuprolide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in a single daily dose and further being adapted to provide multiple portions of solution said while the reservoir remains sterile.. .
|Manufacture of a triiodinated contrast agent|
A new compound, (s)-5-(2-acetoxypropanamido)-2,4,6-triiodoisophthalic acid, of formula ii (s)-5-(2-acetoxypropanamido)-2,4,6-triiodoisophthalic acid. Said new compound is of use for the production of triiodinated contrast agent, especially lopamidol, with low content of acetyl and hydroxyacetyl analogs.
|Heat aging resistant ethylene vinyl acetate copolymer composition and process for its production|
Heat resistant ethylene vinyl acetate copolymer compositions comprising a blend of ethylene vinyl acetate copolymer, peroxide curable polyacrylate elastomer, and polyamide are described. When crosslinked with a peroxide curative, the ethylene vinyl acetate copolymer compositions exhibit enhanced resistance to heat aging compared to conventional ethylene vinyl acetate elastomer compositions..
|Process and intermediates for the preparation of abiraterone acetate|
The present invention relates to a process for the synthesis of (3beta)17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate (abiraterone acetate) represented by the structure of formula (1), and salts thereof, especially salts with pharmaceutically acceptable acids. The present invention further relates to certain intermediates in such processes..
|Composition and process for mercury removal|
A process for removing mercury from a gas or liquid phase, wherein the gas or liquid phase containing mercury is placed in contact with a composition comprising a precipitated metal sulfide. The precipitated metal sulfide may be made by the process of combining a metal source, sulfide source, and modifier to form the precipitated metal sulfide.
The invention provides methods and systems for the production of lipid products from a gaseous substrate using a two stage fermentation process. The method comprises providing a gaseous substrate comprising co or co2 and h2 or mixtures thereof, to a first bioreactor containing a culture or one or more microorganisms, and fermenting the substrate to produce acetate.
|Fast acting inhibitor of gastric acid secretion|
The present invention relates to the use of pharmaceutically acceptable zinc salts, in particular, zinc chloride and zinc acetate, alone or optionally, in combinations with one or more of a protein pump inhibitor (ppi), h2 blocker, anti-h. Pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, including acid secretion in the fundus (by inhibiting vacuolar h+-atpase or h+/k+-atpase) and upper body region of the stomach (by inhibiting h+/k+-atpase), thus raising the ph of gastric juices in rapid fashion and decreasing the duration of stomach acid release during a secretagogue phase.
|Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis|
The present invention provides methods of producing dosage forms for formulas of elemental compositions encompassing acetate salts of calcium, magnesium and zinc along with vitamin d3. The acetate salts could be extracted from natural sources such as pearls, coral, and oyster or compounded using synthetic materials.
|Intravaginal delivery system|
The present invention in general relates to an intravaginal delivery system as well as uses thereof and methods for manufacturing and use of the same. In particular the present invention relates to an intravaginal delivery system for the controlled release of one or more organic acids, such as lactic acid; said intravaginal delivery system being characterized in that it comprises a combination of ethylene vinyl acetate (eva) copolymers and carboxylic polymers, such as for example methacrylic acid-methacrylic ester copolymers..
|Heat-conducting and heat-dissipating nano-materials, preparing method thereof and heat-dissipating system|
The invention provides a heat-conducting and heat-dissipating nano-material, a method for preparation thereof and a heat-dissipating system. The method comprises the following steps: i) mixing a complex formed by a high molecular material and a substance having heat conduction and heat dissipation properties with tert-butyl acetate and 4-chlorobenzotrifluoride, wherein the complex is of nano scale in particle size; and ii) placing a mixture obtained from step i) into water and stirring the mixture in water for a period of time to afford the heat-conducting and heat-dissipating material.
|Sulfite softwood based cellulose triacetate for lcd films|
The invention provides a way of using cellulose triacetate (cta) made from softwood pulp to make films suitable for use in liquid crystal displays (lcds). It has been surprisingly found that a combination of certain additives in the film casting dope and of metal and sulfur content of the cta allow a softwood cta to exhibit peeling characteristics from the casting substrate that are similar to those of lint-based cta of similar sulfur content.
|Phase change ink containing ethylene vinyl acetate|
A phase change ink composition including an ink vehicle; an optional colorant; and ethylene vinyl acetate in an amount of from about 0.1 to about 10 percent by weight based on the total weight of the phase change ink composition.. .
|Combined column for separating products of different hydrogenation reactors|
Recovery of ethanol from a crude product comprising ethyl acetate obtained from the hydrogenation of acetic acid. The crude product is separated to form an organic stream that may be subjected to hydrogenolysis to form ethanol.
|Process for producing ethanol from methyl acetate|
The present invention relates to a process for producing ethanol by methyl acetate hydrogenolysis. The process comprises the step of reacting carbon monoxide and methanol in a reaction medium to form a reaction solution that comprises acetic acid and from 0.5 to 25 wt.
|Methods and compounds for treating cancer|
The invention includes, in part, methods and compounds for treating cancer including, but not limited to gliomas, melanomas, and neuroblastomas. In some embodiments of the invention, a glyceryltriacetate compound is administered to a subject in an amount effective to treat or prevent a cancer in the subject..
|Caspofungin acetate formulations|
A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture..
The invention provides methods and systems for the production of lipid products from a gaseous substrate using a two stage fermentation process. The method comprises providing a gaseous substrate comprising co, co2 and h2 or mixtures thereof, to a first bioreactor containing a culture or one or more microorganisms, and fermenting the substrate to produce a product comprising acetate.
|Halogen-free crosslinked resin composition and insulated wire and cable using the same|
A halogen-free crosslinked resin composition includes a base polymer including as a main component (a) an ethylene vinyl acetate copolymer and (b) an acid modified polyolefin resin having a differential scanning calorimetry glass transition temperature tg of not higher than −55 degrees celsius in a mass ratio (a):(b) of 70:30 to 100:0, the base polymer including 50 to 70% by mass of vinyl acetate, 0.5 to 10 parts by mass of a silicone rubber with respect to 100 parts by mass of the base polymer, and 100 to 250 parts by mass of a metal hydroxide with respect to 100 parts by mass of the base polymer.. .
The present application is directed to articles useful as graphic films. Specifically, the present application is directed to an article comprising a film layer, the film layer comprising a polymer blend comprising a thermoplastic polyurethane and a cellulose ester, and an ink layer adjacent to at least one surface of the film.